ABSTRACT
Genome sequences allow quantification of changes in case introductions from abroad and local transmission dynamics. We sequenced 11,357 SARS-CoV-2 genomes from Switzerland in 2020 - the 6th largest effort globally. Using these data, we estimated introductions and their persistence throughout 2020. By contrasting estimates with null models, we estimate at least 83% of introductions were adverted during Switzerland’s border closures. Further, transmission chain persistence roughly doubled after the partial lockdown was lifted. Then, using a novel phylodynamic method, we suggest transmission in newly introduced outbreaks slowed 36 - 64% upon outbreak detection in summer 2020, but not in fall. This could indicate successful contact tracing over summer before overburdening in fall. The study highlights the added value of genome sequencing data for understanding transmission dynamics.
Competing Interest Statement
TS is president of the Swiss National COVID-19 Science Task Force.
Funding Statement
This study was funded by the Swiss National Science Foundation grant 31CA30_196267 (to TS) and ETH Zurich.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available pathogen genome sequence data collected from humans, which can be obtained from GISAID at gisaid.org. The Ethikkommission Nordwest- und Zentralschweiz (EKNZ) ruled on the ethics of genome sequence generation by the Swiss SARS-CoV-2 Sequencing Consortium (S3C) for this research. Ethical approval was waived as only viral material is processed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the analysis is available on GISAID (gisaid.org). Data produced by the Swiss SARS-CoV-2 Sequencing Consortium is available on GISAID (submitting lab: Department of Biosystems Science and Engineering, ETH Zuerich) and the European Nucleotide Archive (ENA) (study: PRJEB38472). All code is available at or linked to from the project GitHub repository https://github.com/SarahNadeau/cov-swiss-phylo.
